Shigeki Ito

Prof. Shigeki Ito

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SIShigeki Ito
Shigeki Ito
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other agents, including alkylators, immunomodulatory drugs, and monoclonal antibodies, have been incorporated into several regimens. This review summarizes the biological effects and the results of clinical trials investigating PI-based combination regimens and novel investigational inhibitors and discusses the future perspective in the treatment of multiple myeloma.

6 August 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
SIShigeki Ito
Shigeki Ito
MIMasako Iwanaga
Masako Iwanaga
KNKisato Nosaka
Kisato Nosaka
YIYoshitaka Imaizumi
Yoshitaka Imaizumi
KIKenji Ishitsuka
Kenji Ishitsuka
CICollaborative Investigators
Collaborative Investigators
Adult T‐cell leukemia‐lymphoma (ATL) is a T‐cell malignancy that is endemic to Japan. In this latest nationwide study of ATL, we collected the data from 4 nationwide registries of patients diagnosed in 2012‐2013; the Hematology Blood Disease, the Skin Cancer Society, the Hospital‐Based Cancer Registries, and information from the hospitals that participated in the Japanese nationwide survey of ATL in 2010‐2011. In the present study, 2614 patients with ATL were diagnosed based on the registries, and 117 departments registered 1042 patients. Among these patients, 984 were eligible for analysis. The median age at diagnosis was 69 y. A larger proportion of patients with ATL older than 70 y was diagnosed with the lymphoma subtype, and more than half of the patients with ATL in the metropolitan areas were born in the human T‐cell leukemia virus type I (HTLV‐1)‐endemic areas of Kyushu/Okinawa, which are almost identical to the findings in our 2010‐2011 study. Additionally, we identified that patients with ATL migrated from the endemic areas for HTLV‐1 to the non‐endemic metropolitan areas. The present study was able to reduce the burden of searching each hospital and to update the clinico‐epidemiological characteristics of a large number of patients with ATL in Japan, suggesting the usefulness and feasibility of the novel data collection method. The establishment of a more sophisticated database management system for ATL is necessary for future continuous surveys.

1 September 2004 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SIShigeki Ito
Shigeki Ito
YIYoji Ishida
Yoji Ishida
TOTatsuo Oyake
Tatsuo Oyake
MSMamiko Satoh
Mamiko Satoh
YAYusei Aoki
Yusei Aoki
KMKazunori Murai
Kazunori Murai
(2004). Clinical and Biological Significance of CD56 Antigen Expression in Acute Promyelocytic Leukemia. Leukemia & Lymphoma: Vol. 45, No. 9, pp. 1783-1789.

9 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SIShigeki Ito
Shigeki Ito
TSTsuyoshi Sato
Tsuyoshi Sato
TMTakahiro Maeta
Takahiro Maeta
The C-X-C chemokine receptor type 4 (CXCR4) is a pleiotropic chemokine receptor that is expressed in not only normal hematopoietic cells but also multiple myeloma cells. Its ligand, stromal cell-derived factor 1α (SDF-1α) is produced in the bone marrow microenvironment. The SDF-1α/CXCR4 axis plays a pivotal role in the major physiological processes associated with tumor proliferation, survival, invasion, dissemination, and drug resistance in myeloma cells. This review summarizes the pleiotropic role of the SDF-1α/CXCR4 axis in multiple myeloma and discusses the future perspective in the SDF-1α/CXCR4 axis-targeted therapies in multiple myeloma.

1 March 2010 in Leukemia Research
Verified
Journal Article
Closed access
SIShigeki Ito
Shigeki Ito
TOTatsuo Oyake
Tatsuo Oyake
KMKazunori Murai
Kazunori Murai
YIYoji Ishida
Yoji Ishida

30 April 2022 in Anticancer Research
Verified
Journal Article
Open access
PDF file
TMTakahiro Maeta
Takahiro Maeta
TSTsuyoshi Sato
Tsuyoshi Sato
KAKazuya Asano
Kazuya Asano
SIShigeki Ito
Shigeki Ito
Background/Aim: Adult T-cell leukemia (ATL) is a peripheral T lymphocytic malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Despite treatment that includes novel agents that have been developed, most of ATL patients relapse and acquire multidrug resistance. As a result, the creation of newer agents is critical. Dimethyl fumarate (DMF) has several effects in cancer cells, including cell signaling, proliferation and cell death. However, its antitumor effects on ATL cells remain unknown. In this study, we looked at DMF’s antitumor effects on ATL cells. Materials and Methods: We examined the effects of DMF on proliferation and apoptosis using the trypan blue exclusion assay and annexin V/propidium iodide staining in HTLV-1-infected and transformed T-cell lines, MT-1 and MT-2 cells. We also evaluated the effects of DMF on the nuclear factor-kappa B (NF-κB) and signal transducers and activators of transcription 3 (STAT3) signaling pathways and anti-apoptotic proteins by immunoblotting. Results: DMF inhibited proliferation and induced apoptosis in MT-1 and MT-2 cells by activating poly ADP-ribose polymerase (PARP). Furthermore, DMF inhibited the constitutive activation of both canonical and non-canonical NF-κB pathways in MT-2 cells and the non-canonical NF-κB pathway in MT-1 cells. DMF also inhibited the constitutive tyrosine phosphorylation of STAT3 and the expression of anti-apoptotic proteins, c-IAP2 and survivin in both cells. Conclusion: These results indicate that DMF inhibits proliferation and induces apoptosis in HTLV-1-infected and transformed T-cells by suppressing NF-κB and STAT3 signaling pathways. DMF should be investigated further as a novel agent for ATL.